Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
bluebird bio, Inc. - Common Stock
(NQ:
BLUE
)
8.500
-0.730 (-7.91%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about bluebird bio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
December 08, 2024
From
bluebird bio, Inc.
Via
Business Wire
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
December 07, 2024
From
bluebird bio, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 05, 2024
Via
Benzinga
Exploring bluebird bio's Earnings Expectations
November 13, 2024
Via
Benzinga
The Analyst Verdict: bluebird bio In The Eyes Of 5 Experts
September 25, 2024
Via
Benzinga
What 4 Analyst Ratings Have To Say About bluebird bio
August 15, 2024
Via
Benzinga
Why Verint Systems Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
December 05, 2024
Via
Benzinga
bluebird bio Announces 1-for-20 Reverse Stock Split
December 04, 2024
From
bluebird bio, Inc.
Via
Business Wire
FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program
December 04, 2024
CMS launches an outcomes-based model to expand access to FDA-approved gene therapies for sickle cell disease, aiming to improve health outcomes and lower costs.
Via
Benzinga
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
December 04, 2024
From
bluebird bio, Inc.
Via
Business Wire
FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy
November 29, 2024
The FDA is investigating reports of life-threatening blood cancers linked to Skysona, a gene therapy for CALD. Providers are urged to consider safer alternatives and monitor patients for malignancies.
Via
Benzinga
Exposures
Product Safety
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
November 15, 2024
Bluebird Bio's Q3 earnings report showed a narrower-than-expected EPS loss but missed sales targets, leading to a JP Morgan downgrade and cash concerns.
Via
Benzinga
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
November 14, 2024
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call
November 06, 2024
From
bluebird bio, Inc.
Via
Business Wire
Earnings Scheduled For November 14, 2024
November 14, 2024
Via
Benzinga
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
November 05, 2024
From
bluebird bio, Inc.
Via
Business Wire
Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy
October 11, 2024
A recent report reveals an increase in cancer cases among children treated with Bluebird Bio's Skysona gene therapy, raising concerns about the therapy's safety. Seven children in clinical trials have...
Via
Benzinga
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2024
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing
September 27, 2024
From
bluebird bio, Inc.
Via
Business Wire
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
September 26, 2024
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.
Via
Investor's Business Daily
Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year
September 24, 2024
Bluebird bio announces restructuring plans to reduce costs by 20% and achieve cash flow break-even by late 2025. The initiative includes a 25% workforce reduction and focuses on advancing key gene...
Via
Benzinga
bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025
September 24, 2024
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q
September 13, 2024
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces September Investor Events
August 28, 2024
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces Receipt of Expected Notices from Nasdaq
August 23, 2024
From
bluebird bio, Inc.
Via
Business Wire
This Snowflake Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
August 15, 2024
Via
Benzinga
bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
August 14, 2024
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces Second Quarter 2024 Results Call Date
August 12, 2024
From
bluebird bio, Inc.
Via
Business Wire
CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024
August 02, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
bluebird bio, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.